BioInformant to Sponsor “Cell & Gene Therapy World” and “Stem Cells In Vitro” Conferences

Cade Hildreth (CEO)

8 years ago

BioInformant is proud and honored to be sponsoring the upcoming conferences “Cell and Gene Therapy World” (#CGTWorld) and “Stem Cells In Vitro” (#SCin). Hosted by the renowned conference organizer Phacilitate, the events are being held in combination with each other on January 25-27th, 2016, at the Grand Hyatt Hotel in Washington, DC. In addition to sponsoring the event, BioInformant will be attending the event.

We will be bringing you:

Live tweeting of the event (connect with us on Twitter @StemCellMarket and follow the event hashtags #CGTWorld and #SCiv)
Live event coverage across a variety of social media platforms – LinkedIn, Facebook, Pinterest, and more
Live blogging about the event to be published at BioInformant.com and Bioleaders-forum.com
Professional quality event images on Flickr

The event is the “world’s first and only genuinely global cell and gene therapy event” promising to draw together key stakeholders from across North America, European Union, Asia, Oceania, and other regions worldwide. The event will explore “financing, research and development (R&D), manufacturing and commercialization opportunities within cell and gene therapy markets.”

If you are also attending the event, I welcome you to connect with us at the event or set-up a 1-on-1 meeting by emailing Info@BioInformant.com. In addition to being the first and only market research firm to specialize in stem cell markets, we are looking to interview major players within the stem cell industry (executives and investors). These interviews will be featured on our stem cell industry blog, BioInformant.com, and shared across our wide range of distribution platforms, including Twitter, LinkedIn, Facebook, Pinterest, Flickr, as well as to our email mailing list that includes thousands of stem cell industry participants.

To learn more about the event, visit:
http://www.bioleaders-forum.com/Content/Investment-Insights/3_25/

5/5 - (1 vote)